IL112059A - Transdermal therapeutic composition containing a deuterated active substance with penetration-enhancing effect - Google Patents

Transdermal therapeutic composition containing a deuterated active substance with penetration-enhancing effect

Info

Publication number
IL112059A
IL112059A IL11205994A IL11205994A IL112059A IL 112059 A IL112059 A IL 112059A IL 11205994 A IL11205994 A IL 11205994A IL 11205994 A IL11205994 A IL 11205994A IL 112059 A IL112059 A IL 112059A
Authority
IL
Israel
Prior art keywords
penetration
composition containing
active substance
therapeutic composition
transdermal therapeutic
Prior art date
Application number
IL11205994A
Other languages
English (en)
Other versions
IL112059A0 (en
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of IL112059A0 publication Critical patent/IL112059A0/xx
Publication of IL112059A publication Critical patent/IL112059A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL11205994A 1993-12-22 1994-12-19 Transdermal therapeutic composition containing a deuterated active substance with penetration-enhancing effect IL112059A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4343838A DE4343838C2 (de) 1993-12-22 1993-12-22 Deuteriertes Arzneimittel in transdermaler Applikation und Verfahren zu seiner Herstellung

Publications (2)

Publication Number Publication Date
IL112059A0 IL112059A0 (en) 1995-03-15
IL112059A true IL112059A (en) 1999-06-20

Family

ID=6505771

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11205994A IL112059A (en) 1993-12-22 1994-12-19 Transdermal therapeutic composition containing a deuterated active substance with penetration-enhancing effect

Country Status (21)

Country Link
US (1) US5895660A (fi)
EP (1) EP0737069B1 (fi)
JP (1) JP4451494B2 (fi)
KR (1) KR100371810B1 (fi)
AT (1) ATE237331T1 (fi)
AU (1) AU706814B2 (fi)
CA (1) CA2179778C (fi)
CZ (1) CZ180496A3 (fi)
DE (2) DE4343838C2 (fi)
DK (1) DK0737069T3 (fi)
ES (1) ES2197187T3 (fi)
FI (1) FI962550A (fi)
HU (1) HUT75700A (fi)
IL (1) IL112059A (fi)
MY (1) MY111718A (fi)
NO (1) NO962655L (fi)
NZ (1) NZ277036A (fi)
PL (1) PL178036B1 (fi)
SK (1) SK82596A3 (fi)
WO (1) WO1995017188A1 (fi)
ZA (1) ZA9410211B (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4427690A1 (de) * 1994-08-04 1996-02-08 Bogdahn Ulrich Prof Deuterium enthaltende pharmazeutische Zusammensetzung als Zytostatikum oder Tumor-Therapeutikum
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
DE10129832A1 (de) * 2001-06-17 2003-07-10 Berolina Drug Dev Ab Svedala Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel
US6872408B2 (en) * 2001-09-07 2005-03-29 Rupert C. Bell Method of treating bipolar disorders using deuterium-substituted carbonate
DE10214228A1 (de) * 2002-03-22 2003-10-02 Bdd Group Holding Ag Zug Deuterierte substitutierte Indole sowie diese Verbindungen enthaltende Arzneimittel
JP2010501011A (ja) 2006-08-16 2010-01-14 オースペックス・ファーマシューティカルズ・インコーポレイテッド オピオイド鎮痛薬の調製および効用
DE102007031397A1 (de) * 2007-07-05 2009-01-08 D2O Bioscience Group Ltd. Verwendung von Deuteriumoxid zur Behandlung von Virus-basierten Erkrankungen der Haut
AU2009270936B2 (en) * 2008-07-15 2014-12-18 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
EP2331140B1 (en) 2008-08-11 2018-07-04 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
US8658236B2 (en) 2009-08-21 2014-02-25 Deuteria Beverages, Llc Alcoholic compositions having a lowered risk of acetaldehydemia
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US20130338216A1 (en) 2010-12-22 2013-12-19 Nektar Therapeutics Deuterated and/or fluorinated taxane derivatives
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US8778223B2 (en) 2011-05-24 2014-07-15 Lc Vision, Llc Liquid crystals having cyclohexyl core structures and fluorinated tails

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
SE426011B (sv) * 1976-01-30 1982-12-06 Sixten Abrahamsson Anvendning av en helt eller partiellt deutererad acyklisk, enbasisk karboxyylayra for att skydda ett material i form av levande vexter, utsede och tre mot skadliga svampar
US4475585A (en) * 1981-06-11 1984-10-09 Snyder General Corporation Air conditioning and heat pump cabinets with removable coil guards
US4529600A (en) * 1982-09-09 1985-07-16 Sri International Pentadeuterioretinoids
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4898855A (en) * 1987-09-14 1990-02-06 Hoffman-La Roche Inc. Deuterated analogs of 1,25-dihydroxycholecalciferol
US4876260A (en) * 1987-10-28 1989-10-24 State Of Israel, Israel Institute Of Biological Research Oxathiolanes
US5075337A (en) * 1989-07-26 1991-12-24 G. D. Searle & Co. Alpha-deuterated 2-alkylaminoacetamide derivatives having reduced toxicity for treatment of CNS disorders
GB9201275D0 (en) * 1992-01-21 1992-03-11 Norsk Hydro As New compounds

Also Published As

Publication number Publication date
SK82596A3 (en) 1997-03-05
HUT75700A (en) 1997-05-28
DE59410275D1 (de) 2003-05-22
ZA9410211B (en) 1996-02-06
EP0737069B1 (de) 2003-04-16
ES2197187T3 (es) 2004-01-01
KR100371810B1 (ko) 2003-07-22
FI962550A (fi) 1996-08-13
MY111718A (en) 2000-11-30
ATE237331T1 (de) 2003-05-15
JP4451494B2 (ja) 2010-04-14
FI962550A0 (fi) 1996-06-19
CA2179778A1 (en) 1995-06-29
NO962655D0 (no) 1996-06-21
AU706814B2 (en) 1999-06-24
US5895660A (en) 1999-04-20
JPH09506874A (ja) 1997-07-08
PL315127A1 (en) 1996-10-14
DE4343838A1 (de) 1995-06-29
CA2179778C (en) 2005-09-06
CZ180496A3 (en) 1997-02-12
NO962655L (no) 1996-08-20
WO1995017188A1 (de) 1995-06-29
NZ277036A (en) 1998-06-26
HU9601684D0 (en) 1996-08-28
DE4343838C2 (de) 1998-07-09
IL112059A0 (en) 1995-03-15
DK0737069T3 (da) 2003-07-28
PL178036B1 (pl) 2000-02-29
EP0737069A1 (de) 1996-10-16
AU1191795A (en) 1995-07-10

Similar Documents

Publication Publication Date Title
PT99513A (pt) Processo para a preparacao de composicoes farmaceuticas contendo profarmacos de morfina para administracao topica por via transdermica
IL112059A (en) Transdermal therapeutic composition containing a deuterated active substance with penetration-enhancing effect
AR003989A1 (es) Composicion cosmetica o farmaceutica y procedimiento de tratamiento cosmetico, excluido tdo tratamiento terapeutico que utiliza la composicion cosmetica.
AU1537095A (en) Therapeutic agents containing thyroid hormones
DE69432752D1 (de) Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält
ES2084390T3 (es) Comprimidos de liberacion controlada, de varias capas, que contienen tanto naproxen como sal sodica de naproxen.
FR2728463B1 (fi)
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
HK1030604A1 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
EP0137543A3 (en) Pharmaceutical composition for the therapy of peripheral arteriopathies
AP1901A (en) Pharmaceutical composition for modified release insulin sensitiser.
DK0714304T3 (da) Terapeutisk system til behandling af psoriasis
AU533524B2 (en) 6-substituted-11-alkylene morphanthridines
GB1474424A (en) Pharmaceutical composition for treating diabetic ketoacidosis
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
BR9407340A (pt) Meio hormonal para tratamento de acne
DE59510583D1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
MX9302986A (es) Medicamento que contiene metrifonato y procedimiento para su preparacion
DK0667774T3 (da) Transdermalt, terapeutisk system til indgivelse af physostigmin genem huden og fremgangsmåde til dets fremstilling
BR9815993A (pt) Comprimido de liberação cronometrada compreendendo naproxen e pseudoefedrina
GR1003059B (el) Βαλσαμινοελαιολαδο προιον αναγεννησης μαλλιων
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.
MX9709684A (es) Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.
IL117734A0 (en) Beta-carbolines and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees